<ul><li>Wanbury Limited, an Indian pharmaceutical company, has been spared from US tariff hikes as part of a broader tariff regime announced by President Trump.</li><li>The new tariffs will impose duties on imported goods, with India facing a 26% tariff rate, significantly lower than China, Vietnam, and Bangladesh.</li><li>Pharmaceuticals, semiconductors, and certain metals have been exempted from the tariffs, benefitting the Indian pharma industry.</li><li>Wanbury Limited is preparing for an investors and analysts plant visit after major plant upgrades and reported improved capacity utilization and higher revenues.</li></ul>

India’s pharma sector spared from US tariff hikes as Wanbury plans investor visit

Discover more